<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>The oral multikinase inhibitor regorafenib targets both <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e> cell proliferation and vasculature and is active in heavily pretreated patients with <z:e sem="disease" ids="C0948380" disease_type="Neoplastic Process" abbrv="">metastatic colorectal cancer</z:e>, for which the US FDA granted its approval in September 2012 </plain></SENT>
<SENT sid="1" pm="."><plain>The benefit for regorafenib was seen in these patients in most prespecified subgroups </plain></SENT>
<SENT sid="2" pm="."><plain>The drug is also being used in other <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e> types where it has shown exciting potential especially in <z:hpo ids='HP_0100723'>gastrointestinal stromal tumors</z:hpo> </plain></SENT>
<SENT sid="3" pm="."><plain>The drug is well tolerated but requires close monitoring during administration </plain></SENT>
<SENT sid="4" pm="."><plain>Common side effects include asthenia/tiredness, loss of appetite, hand-foot skin syndrome, <z:hpo ids='HP_0002014'>diarrhea</z:hpo>, mucositis, <z:hpo ids='HP_0001824'>weight loss</z:hpo>, <z:e sem="disease" ids="C0021311,C0009450" disease_type="Disease or Syndrome" abbrv="">infections</z:e>, <z:hpo ids='HP_0000822'>hypertension</z:hpo> and <z:e sem="disease" ids="C0015230" disease_type="Disease or Syndrome" abbrv="">rash</z:e> </plain></SENT>
<SENT sid="5" pm="."><plain>Serious adverse events to look out for are liver toxicity, <z:mp ids='MP_0001914'>hemorrhage</z:mp> and gastrointestinal <z:mpath ids='MPATH_81'>perforation</z:mpath> </plain></SENT>
<SENT sid="6" pm="."><plain>Biomarker data should help us to optimize the use of these drugs to select which patients are most likely to benefit </plain></SENT>
</text></document>